Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial

(2021) Stephan Kadauke et al.   JOURNAL OF CLINICAL ONCOLOGY

Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells

(2021) Haneen Shalabi et al.   Nature Reviews Clinical Oncology

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

(2021) Patrick A. Brown et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia

(2021) Franco Locatelli et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

(2021) Marie-Emilie Dourthe et al.   LEUKEMIA

Navigating CAR-T cells through the solid-tumour microenvironment

(2021) Andrew J. Hou et al.   NATURE REVIEWS DRUG DISCOVERY

Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

(2021) Regina M. Myers et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

(2021) Haiying Qin et al.   Journal for ImmunoTherapy of Cancer

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

(2020) Andrew D.J. Pearson et al.   EUROPEAN JOURNAL OF CANCER

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells

(2020) Wenqun Zhang et al.   BLOOD

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

(2020) Nirali N. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression

(2020) Kristen Fousek et al.   LEUKEMIA

Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors

(2020) Johanna Theruvath et al.   NATURE MEDICINE

Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma

(2020) Laura K. Donovan et al.   NATURE MEDICINE

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

(2020) Kohei Shitara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study

(2020) Stephanie B. Dixon et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

(2020) Carlos A. Ramos et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children

(2020) Véronique Minard-Colin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma

(2020) Meenakshi Hegde et al.   Nature Communications

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo

(2020) Matteo Libero Baroni et al.   Journal for ImmunoTherapy of Cancer

Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents

(2020) Andrew D.J. Pearson et al.   EUROPEAN JOURNAL OF CANCER

Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to the European Medicines Agency and US Food and Drug Administration

(2020) Gregory Reaman et al.   JOURNAL OF CLINICAL ONCOLOGY

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

(2020) Andras Heczey et al.   NATURE MEDICINE

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

(2020) Nirav N. Shah et al.   NATURE MEDICINE

Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia

(2020) Melissa M. Berrien-Elliott et al.   Cancer Discovery

The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing

(2020) Janice M. Riberdy et al.   Molecular Therapy-Methods & Clinical Development

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

(2020) Frederick L. Locke et al.   Blood Advances

Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management

(2020) Shiqi Li et al.   CLINICAL CANCER RESEARCH

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

(2020) Reuben Benjamin et al.   LANCET

Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

(2020) Karin Straathof et al.   Science Translational Medicine

CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

(2019) Robbie G. Majzner et al.   CLINICAL CANCER RESEARCH

NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors

(2019) Robin Parihar et al.   Cancer Immunology Research

Chimeric Antigen Receptors for T-Cell Malignancies

(2019) Lauren D. Scherer et al.   Frontiers in Oncology

Driving CAR T cell translation forward

(2019) Liora Schultz et al.   Science Translational Medicine

ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children

(2019) Andrew D.J. Pearson et al.   EUROPEAN JOURNAL OF CANCER

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells

(2019) Kevin A. Hay et al.   BLOOD

CD19 CAR T cell product and disease attributes predict leukemia remission durability

(2019) Olivia C. Finney et al.   JOURNAL OF CLINICAL INVESTIGATION

CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia

(2019) Jing Pan et al.   LEUKEMIA

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

(2019) Kenji Tamura et al.   LANCET ONCOLOGY

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

(2019) Sara Ghorashian et al.   NATURE MEDICINE

Clinical lessons learned from the first leg of the CAR T cell journey

(2019) Robbie G. Majzner et al.   NATURE MEDICINE

Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012

(2018) Mareike Rasche et al.   LEUKEMIA

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

(2018) Matthew L Cooper et al.   LEUKEMIA

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas

(2018) Christopher W. Mount et al.   NATURE MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259 T Cells in Synovial Sarcoma

(2018) Sandra P. D'Angelo et al.   Cancer Discovery

Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma

(2018) Concetta Quintarelli et al.   OncoImmunology

CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping

(2018) Anne E. Bras et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

(2018) Haiying Qin et al.   Molecular Therapy-Oncolytics

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531

(2017) Jatinder K. Lamba et al.   JOURNAL OF CLINICAL ONCOLOGY

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma

(2017) Nan Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

(2017) Nabil Ahmed et al.   JAMA Oncology

Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility

(2016) Annette Künkele et al.   CLINICAL CANCER RESEARCH

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531

(2016) Jessica A. Pollard et al.   JOURNAL OF CLINICAL ONCOLOGY

CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia

(2016) Challice L Bonifant et al.   MOLECULAR THERAPY

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

(2016) Rizwan Romee et al.   Science Translational Medicine

A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies

(2015) M. Mamonkin et al.   BLOOD

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232

(2015) M. J. Borowitz et al.   BLOOD

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein

(2015) H. Qin et al.   BLOOD

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

Pediatric AML: From Biology to Clinical Management

(2015) Jasmijn de Rooij et al.   Journal of Clinical Medicine

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy

(2014) A. Heczey et al.   BLOOD

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

(2014) Alan S. Gamis et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Therapeutic Approaches for Pediatric Acute Myeloid Leukemia

(2014) Sarah K. Tasian et al.   Frontiers in Oncology

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

(2013) A. Mardiros et al.   BLOOD

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

(2012) W. Haso et al.   BLOOD

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

(2012) J. A. Pollard et al.   BLOOD

IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity

(2012) Daofeng Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies

(2011) V. Blanc et al.   CLINICAL CANCER RESEARCH

Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages

(2009) Liping Song et al.   JOURNAL OF CLINICAL INVESTIGATION

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE